Souza, Rogerio de 
; Delcroix, Marion; Galie, Nazzareno; Jansa, Pavel; Mehta, Sanjay; Pulido, Tomas; Rubin, Lewis; Sastry, B. K. S; Simonneau, Gerald; Sitbon, Olivier
Source: Advances in therapy. Unidade: FM
Subjects: ESTUDOS RANDOMIZADOS, HIPERTENSÃO PULMONAR, TERAPIA COMBINADA, SOBREVIDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Rogerio de et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Advances in therapy, v. 39, n. 9, p. 4374-4390, 2022Tradução . . Disponível em: https://doi.org/10.1007/s12325-022-02199-x. Acesso em: 26 jun. 2025.APA
Souza, R. de, Delcroix, M., Galie, N., Jansa, P., Mehta, S., Pulido, T., et al. (2022). Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Advances in therapy, 39( 9), 4374-4390. doi:10.1007/s12325-022-02199-xNLM
Souza R de, Delcroix M, Galie N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension [Internet]. Advances in therapy. 2022 ; 39( 9): 4374-4390.[citado 2025 jun. 26 ] Available from: https://doi.org/10.1007/s12325-022-02199-xVancouver
Souza R de, Delcroix M, Galie N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension [Internet]. Advances in therapy. 2022 ; 39( 9): 4374-4390.[citado 2025 jun. 26 ] Available from: https://doi.org/10.1007/s12325-022-02199-x
